secwatch / observer
8-K filed March 5, 2024, 6:59 PM ET ticker BNGO CIK 0001411690
other material confidence high sentiment negative materiality 0.85

Bionano Genomics, Inc. (BNGO): restructuring charge — Bionano Genomics reports Q4 revenue $10.7M (+30% YoY), announces 34-39% workforce reduction

Bionano Genomics, Inc.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Bionano Genomics, Inc. reported the fourth quarter and full year ended December 31, 2023 results: revenue $10.7 million.

Period
the fourth quarter and full year ended December 31, 2023
Revenue
$10.7 million
Result
reported results
Exact text from the filing
Bionano Reports Fourth Quarter and Full-Year 2023 Results and Provides Revenue Outlook for 2024 • Q4 2023 revenue was $10.7 million , which represents a 30% increase over Q4 2022 • FY 2023 revenue was $36.1 million , which represents a 30% increase over FY 2022
View on SEC.gov
Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Bionano Genomics, Inc. announced a restructuring affecting global operations (approximately 110 to 125 employees).

Type
restructuring
Affected area
global operations
Headcount
approximately 110 to 125 employees
Exact text from the filing
On March 1, 2024, the Company committed to a corporate reorganization plan (the “Plan”), including a reduction in force (the “Reduction”) intended to decrease expenses and maintain a streamlined organization to support key programs that are expected to drive long-term growth.
View on SEC.gov

13 earnings releases filed in the last 30 days. Browse all earnings releases →

Bionano Genomics, Inc. filing history →

Source: SEC EDGAR
accession 0001411690-24-000004
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.